We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Antenatal Urine Samples Screened for Chlamydia

By LabMedica International staff writers
Posted on 19 Apr 2011
Urine samples from pregnant women have been successfully screened to identify those infected with Chlamydia trachomatis.

The urine screening was conducted using a commercial molecular assay utilizing target capture for the in vitro qualitative detection and differentiation of ribosomal RNA (rRNA) of C. More...
trachomatis and Neisseria gonorrhoeae.

Scientists at University of Texas Southwestern Medical Center, (Dallas, TX, USA), tested a total of 2,018 pregnant women whose mean age was 26.9 years old, and of whom 84% were Hispanic. For four months, all women who were seen at a group of family planning and obstetric complication clinics in the area and who were between 35 and 37 weeks pregnant were tested. Both urine samples and endocervical secretions were assayed.

All samples were analyzed using the Aptima Combo 2 Assay, which is a target amplification nucleic acid probe test. The prevalence of Chlamydia according to tests of cervical secretions was 4.3% compared to 4.1% using urine sampling. The results from the two samplings were considered to be almost perfectly concordant. Sensitivity of urine screening was 96.5% relative to endocervical screening where the 95% confidence interval (CI) was 90.1% to 99.3%, with a relative specificity of 100%.

Urine screening for Chlamydia has shown to be accurate in male and nonpregnant female populations using Aptima Combo 2 Assay (Gen-Probe Inc.; San Diego, CA, USA). However, the scientists were uncertain that would translate to effectiveness in pregnant women. Their concern was that pregnant women might have amplification inhibitors not present in the nonpregnant population leading to nucleic acid amplification tests being less sensitive when performed on urine as compared with cervical specimens. However, this proved not to be the case.

Scott W. Roberts, MD, lead author of the study, said, "Removing the need for a speculum examination with its potential benefits in costs and respect for patients' desires has led us to use urine nucleic acid amplification testing for our C. trachomatis screening in all pregnant women." Urine sampling is also considerably cheaper than endocervical sampling, and scores points with patients who would rather not undergo an invasive exam. Chlamydia trachomatis is the most common bacterial sexually transmitted infection in the US. This disease disproportionately affects adolescent minority women, and untreated infection can lead to lasting reproductive tract morbidity. The study was published in the April 2011, edition of Obstetrics & Gynecology.

Related Links:
University of Texas Southwestern Medical Center
Gen-Probe Incorporated


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.